Bio-Path Holdings Appoints Martina Molsbergen to Board of Directors
October 15 2019 - 8:00AM
Bio-Path Holdings, Inc., (NASDAQ: BPTH), a biotechnology company
leveraging its proprietary DNAbilize® antisense RNAi nanoparticle
technology to develop a portfolio of targeted nucleic acid cancer
drugs, today announces the appointment of Martina Molsbergen, Chief
Executive Officer of C14 Consulting, to its Board of Directors,
effective as of October 11, 2019. Ms. Molsbergen replaced Mark
Colonnese, who stepped down from the Board of Directors on October
10, 2019.
“We are delighted to welcome Martina to our Board
of Directors. Her considerable experience in business development
will be invaluable as we seek a variety of partnerships and
collaborations in order to advance our DNAbilize platform
technology. We look forward to benefitting from her insight and
experience in the life science sector,” said Peter Nielsen,
President and Chief Executive Officer of Bio-Path Holdings. “We
thank Mark Colonnese for his considerable contributions to the
Board over the last two years and wish him continued success in his
endeavors.”
Prior to establishing C14 Consulting, a business
development advisory firm catering to the life sciences community,
Ms. Molsbergen served as Vice President of Business Development of
Crucell Holland BV. Before that, Ms. Molsbergen served as Vice
President of Business Development of Biowa, Inc. Earlier, she
served as Vice President of Business Development of Zetiq
Technologies Ltd. and as Vice President of Pharmaceutical
Development Services & Business Development of Patheon Inc. Ms.
Molsbergen holds a B.S. in Chemical Engineering from Drexel
University. About Bio-Path Holdings, Inc.
Bio-Path is a biotechnology company developing
DNAbilize®, a novel technology that has yielded a pipeline of RNAi
nanoparticle drugs that can be administered with a simple
intravenous transfusion. Bio-Path’s lead product candidate,
prexigebersen (BP1001, targeting the Grb2 protein), is in a Phase 2
study for the treatment of blood cancers and is in the process of
filing an IND for a Phase 1 clinical trial for solid tumors. The
Company is also developing BP1002, which targets the Bcl-2 protein
and is expected to be evaluated for the treatment of lymphoma and
solid tumors. In addition, BP1003, a novel liposome- incorporated
STAT3 antisense oligodeoxynucleotide developed by Bio Path as a
specific inhibitor of STAT3, is expected to enter Phase 1 studies
in 2020.
For more information, please visit the Company's website
at http://www.biopathholdings.com.Forward-Looking
Statements
This press release contains forward-looking statements that are
made pursuant to the safe harbor provisions of the federal
securities laws. These statements are based on management's current
expectations and accordingly are subject to uncertainty and changes
in circumstances. Any express or implied statements contained in
this press release that are not statements of historical fact may
be deemed to be forward-looking statements. Any statements that are
not historical facts contained in this release are forward-looking
statements that involve risks and uncertainties, including
Bio-Path’s ability to raise needed additional capital on a timely
basis in order for it to continue its operations, Bio-Path's
ability to have success in the clinical development of its
technologies, the timing of enrollment and release of data in such
clinical studies and the accuracy of such data, limited patient
populations of early stage clinical studies and the possibility
that results from later stage clinical trials with much larger
patient populations may not be consistent with earlier stage
clinical trials, the maintenance of intellectual property rights,
that patents relating to existing for future patent applications
will be issued or that any issued patents will provide meaningful
protection of our drug candidates, risks relating to maintaining
Bio-Path's listing on the Nasdaq Capital Market and such other
risks which are identified in Bio-Path's most recent Annual Report
on Form 10- K, in any subsequent quarterly reports on Form 10-Q and
in other reports that Bio-Path files with the Securities and
Exchange Commission from time to time. These documents are
available on request from Bio-Path Holdings or at www.sec.gov.
Bio-Path disclaims any intention or obligation to update or revise
any forward-looking statements, whether as a result of new
information, future events or otherwise.
Contact
Information:Investors
Will O’ConnorStern Investor Relations,
Inc.212-362-1200will@sternir.com
Doug MorrisInvestor RelationsBio-Path Holdings,
Inc.832-742-1369
Bio Path (NASDAQ:BPTH)
Historical Stock Chart
From Aug 2024 to Sep 2024
Bio Path (NASDAQ:BPTH)
Historical Stock Chart
From Sep 2023 to Sep 2024